The drug against erectile dysfunction burst onto the pharmaceutical market in March 1998 at the hands of the Pfizer laboratory.
Legend has it that Alexander Fleming was eating a sandwich in the laboratory while studying bacteria in 1928. Some breadcrumbs fell on his culture by accident. A few days later, he realized that a dirty mold had killed all the bacteria and, instead of sterilizing the laboratory, he decided to study this mold, discovering what is now known as penicillin, the first antibiotic in history.
Most of the great discoveries in the field of health in relation to drugs were made inadvertently, by mistake or by accident. And as happened to Fleming with penicillin, it also happened with 비아그라 판매, which has revolutionized sexual life since it was launched in the United States at the initiative of the Pfizer laboratory in March 1998 .
What is 비아그라 판매? This is how Wikipedia explains it : Sildenafil (compound UK-92,480), sold under the brand name 비아그라 판매, Revatio and others, is a drug used to treat erectile dysfunction and pulmonary arterial hypertension (PPH). It was originally developed by British scientists and later brought to market by the pharmaceutical company Pfizer. It acts by inhibiting cyclic GMP-specific phosphodiesterase type 5 (PDE5), an enzyme that promotes the breakdown of cGMP, which regulates blood flow. on the penis
Medicine’s Most Profitable Mistake
The pharmaceutical company Pfizer was looking for a drug that aimed to improve blood circulation in people suffering from angina pectoris , a disorder in the cardiac system that affects the blood vessels of the heart, causing them not to pump enough blood and therefore affecting limbs and the rest of the body.
In 1980, the biochemist Robert Furchgott demonstrated the existence of a powerful endogenous vasodilator synthesized by the endothelium, the tissue that lines the inner area of blood vessels, and the discovered vasodilator was called endothelium-derived relaxing factor. In 1986, Louis Ignarro and Salvador Moncada identified it as nitric oxide (NO) and Ferid Murad demonstrated its ability to increase levels of cyclic guanosine monophosphate (cGMP), a key messenger in smooth muscle cells: it relaxes smooth muscle cells of blood vessels, relaxation of vascular smooth muscle leads to vasodilation and increased blood flow.
All these discoveries allowed laying the foundations of the molecular mechanism of vasodilation mediated by nitric oxide. However, both nitroglycerin and other organic nitrates, used later as an exogenous source of nitric oxide, which increase cGMP, their prolonged administration generates pharmacological tolerance and they cease to have an effect . This tolerance is due to the oxidation of certain cysteine residues, which results in their inactivation. This phenomenon is what led to the development of new vasodilators that are guanylate cyclase activators, whose mechanism does not involve the production of nitric oxide, or phosphodiesterase 5 inhibitors.Sildenafil, synthesized by Pfizer in the late 1980s, is the first selective inhibitor for phosphodiesterase 5, showing great inhibitory potency and excellent selectivity.
The first clinical trials for the development of sildenafil as an angina treatment, in which the drug was administered to healthy volunteers, began in 1991. The results were disastrous, and Pfizer came close to terminating the project. But the side effects surprised the researchers: Some of the volunteers reported altered color perception, headache and penile erection .